History of the Daiichi Sankyo Group

The Daiichi Sankyo Group leverages its century-long strengths in Science & Technology (S&T) forged by its predecessors to continue to take on the challenge of creating advanced pharmaceutical products. Harnessing S&T as the driving force, we will continue to create innovative pharmaceuticals and realizing Healthcare as a Service (Haas*) by developing both a total care ecosystem and a total care platform through collaboration with other companies as we work toward our 2030 Vision and thereby “contribute to the enrichment of quality of life around the world.”

* Haas refers to providing healthcare and medical services that are optimized and tailored to each individual by utilizing a variety of data and advanced technologies.

**Steps of our 5-year business plan**

**History as a Partner to Patients for over 100 years**

The Daiichi Sankyo Group manufactured the first antibiotic produced in Japan: Taka-Diastase in 1899.

**1902** Adrenalin, an adrenal cortex hormone agent

**1910** Acetylcholine chloride, a cholinergic agent, established a foundation for the theory of vitamins

**1915** Manufactured Mevalon, a vitamin B2 alkaloid

**1922** Launched Minol®, a broad-spectrum oral antibiotic

**1925** Launched Jumex®, an antihypertensive agent

**1935** Launched Adrane®, a sympathomimetic amine

**1939** Launched Lomotil®, an anti-diarrheal agent

**1945** Launched Nalorphine®, an opium narcotic and an anti-inflammatory agent

**1951** Launched Intravenol®, an antihistamine and a sedative-hypnotic agent

**1955** Launched Hydralazine®, a drug used in the treatment of hypertension

**1959** Launched Lomeldin®, an anti-arrhythmic

**1965** Launched Tack®, a broad-spectrum oral antibiotic

**1966** Launched Lomax®, an anti-ulcer agent

**1970** Launched Cravit®, an anticoagulant

**1971** Launched Benicar®, a broad-spectrum oral antihypertensive agent

**1975** Launched Mevason®, a hypolipidemic

**1978** Launched Trecce®, an anti-asthmatic agent

**1980** Launched Tarivid®, a broad-spectrum oral antibiotic

**1982** Launched Lonapine®, a major tranquilizer

**1985** Launched Loxonin®, an anti-infective agent

**1986** Launched Transamin®, an anti-malarial agent

**1988** Transformed into a group holding company

**1990** Launched Maxibear®, an anti-ulcer agent

**1992** Transformed into a public company

**1993** Launched Mevalon®, a broad-spectrum oral antibiotic

**1995** Launched Gemfibrozil®, a blood fat-lowering agent

**1996** Launched Cholester®, an anti-cholesterol agent

**1999** Launched Fluvastatin®, the first statin produced in Japan

**2000** Launched Benicar®, an antihypertensive agent

**2002** Launched Cravit®, an anticoagulant

**2005** Launched Tarivid®, a broad-spectrum oral antibiotic

**2009** Launched Efient®, an anti-platelet agent

**2010** Launched Inavir®, an anti-influenza treatment

**2011** Launched Lixiana®, an anticoagulant

**2012** Launched Benicar®, an antihypertensive agent

**2013** Launched Tarivid®, a broad-spectrum oral antibiotic

**2014** Launched Epogen®, an erythropoietin stimulating agent

**2015** Launched Tarivid®, a broad-spectrum oral antibiotic

**2016** Launched Tarivid®, a broad-spectrum oral antibiotic

**2017** Launched Tarivid®, a broad-spectrum oral antibiotic

**2018** Launched Tarivid®, a broad-spectrum oral antibiotic

**2019** Launched Tarivid®, a broad-spectrum oral antibiotic

**2020** Launched Tarivid®, a broad-spectrum oral antibiotic

**2021** Launched Tarivid®, a broad-spectrum oral antibiotic

**2022** Launched Tarivid®, a broad-spectrum oral antibiotic

**2023** Launched Tarivid®, a broad-spectrum oral antibiotic

**2024** Launched Tarivid®, a broad-spectrum oral antibiotic

**2025** Launched Tarivid®, a broad-spectrum oral antibiotic

**2026** Launched Tarivid®, a broad-spectrum oral antibiotic

**2027** Launched Tarivid®, a broad-spectrum oral antibiotic

**2028** Launched Tarivid®, a broad-spectrum oral antibiotic

**2029** Launched Tarivid®, a broad-spectrum oral antibiotic

**2030** Launched Tarivid®, a broad-spectrum oral antibiotic

**Innovative Global Healthcare Company Contributing to the Sustainable Development of Society**

**5th Term**

Become a “Global Pharma Innovator with a competitive advantage in oncology,” and shift to further growth toward our 2030 Vision

**4th Term**

Promotion of measures toward sustainable growth beyond LOE*

- Focus on dermatology, infectious diseases, rare diseases, and cancer fields
- Establish a foundation for sustainable growth

**3rd Term**

Advancement of global hybrid business model

- Focus on dermatology, infectious diseases, rare diseases, and cancer fields
- Establish a foundation for sustainable growth

**2nd Term**

Maximization of synergy and expansion of growth foundation

- Focus on dermatology, infectious diseases, rare diseases, and cancer fields
- Establish a foundation for sustainable growth

**1st Term**

Transformation to become a Global Pharma Innovator with a competitive advantage in oncology

- Grow beyond LOE*
- Establish a foundation of sustainable growth

**Transition of unmet medical needs throughout time**

Infectious diseases (tuberculosis and pneumonia)

Lifestyle-related diseases

Cancer, dementia, and emerging and re-emerging infectious diseases